期刊
PROSTAGLANDINS & OTHER LIPID MEDIATORS
卷 106, 期 -, 页码 1-7出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2013.07.003
关键词
IP receptor agonists; Prostanoid IP receptors; Rat distal pulmonary arteries; Prostacyclin analogues; MRE-269; Iloprost; Treprostinil
资金
- United Therapeutics Corporation, North Carolina, United States
- University College London, UK.
The prostacyclin (IP) receptor agonists, treprostini I, iloprost and the selexipag metabolite, MRE-269 (ACT-333679) Were evaluated in rat distal pulmonary blood vessels. Small pulmonary arteries and veins were pre-contracted with the thromboxane mimetic, U46619 (25 and 100 nM, respectively), and relaxation determined with and without IP receptor antagonists, RO1138452 and RO3244794. In arteries, treprostinil was a more potent vasorelaxant than iloprost, while the efficacy of iloprost was greater. In pulmonary arteries, treprostinil-induced relaxation was essentially abolished by both IP antagonists (1 mu M), while responses to iloprost were partially inhibited. Both treprostinil and iloprost were equipotent, prominently relaxing pulmonary veins with responses being similarly and partially sensitive to IP antagonists. In contrast, RO1138452 failed to inhibit relaxations to MRE-269 in either pulmonary arteries or veins, suggesting no involvement of typical IP receptors. Thus, rat pulmonary tissues cannot be considered appropriate to assess classical IP receptors using the proposed highly selective non-prostanoid agonist MRE-269, contrasting with the IP receptor agonism profile of prostacyclin analogues, iloprost and treprostinil. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据